<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 13.5: Cardiovascular Health & The 'Window of Opportunity' Hypothesis</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - DEEP BLUE theme for Cardiovascular/Longevity */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #daeaff 60%);
            padding: 0 4px;
            font-weight: 500;
            color: #1e3a8a;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            color: white;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #1e40af 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            display: block;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 1px;
            opacity: 0.9;
        }

        /* Data Table */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        th {
            background: #f1f5f9;
            padding: 15px;
            text-align: left;
            font-weight: 600;
            color: #1e3a8a;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
            color: #4b5563;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f0fdf4;
            border-radius: 8px;
            color: #166534;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 30px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding-top: 25px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
            margin-top: 50px;
        }

        @media (max-width: 768px) {
            .toc-list {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 13: The Menopause Transition & Longevity</p>
            <h1 class="lesson-title">Lesson 13.5: Cardiovascular Health & The 'Window of Opportunity' Hypothesis</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Core Certification Content</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#endothelial"><span class="section-num">1</span>Endothelial Function & Nitric Oxide</a></li>
                <li><a href="#lipids"><span class="section-num">2</span>The Pro-Atherogenic Lipid Shift</a></li>
                <li><a href="#raas"><span class="section-num">3</span>RAAS & Blood Pressure Volatility</a></li>
                <li><a href="#window"><span class="section-num">4</span>The 'Window of Opportunity' Hypothesis</a></li>
                <li><a href="#markers"><span class="section-num">5</span>Advanced Markers: hs-CRP & Homocysteine</a></li>
                <li><a href="#clinical"><span class="section-num">6</span>Clinical Application & Case Study</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Analyze the biochemical mechanism by which <span class="highlight">Estradiol (E2)</span> regulates Nitric Oxide production and vascular compliance.</li>
                <li>Explain the hepatic shift in lipid metabolism that occurs during the menopause transition.</li>
                <li>Evaluate the <span class="highlight">Window of Opportunity</span> hypothesis regarding Hormone Replacement Therapy (HRT) and cardiac risk.</li>
                <li>Identify the interplay between Progesterone and the Renin-Angiotensin-Aldosterone System (RAAS).</li>
                <li>Utilize non-traditional biomarkers to assess subclinical cardiovascular inflammation in aging women.</li>
            </ul>
        </div>

        <h2 id="endothelial">1. Endothelial Function: Estrogen‚Äôs Vascular Shield</h2>
        <p>For decades, the medical community observed that women develop cardiovascular disease (CVD) approximately <span class="highlight">10 years later than men</span>. This "female advantage" is largely attributed to the vasoprotective effects of 17Œ≤-estradiol (E2). However, as women transition through perimenopause, this protection rapidly erodes.</p>
        
        <p>The primary mechanism of estrogenic protection is its interaction with the <span class="highlight">vascular endothelium</span>. Estrogen binds to Estrogen Receptor Alpha (ERŒ±) and Estrogen Receptor Beta (ERŒ≤) located directly on the endothelial cells and smooth muscle cells of the arteries. This binding triggers the activation of <strong>endothelial Nitric Oxide Synthase (eNOS)</strong>.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <span class="stat-number">2-3x</span>
                    <span class="stat-label">Increase in CVD risk post-menopause</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">~50%</span>
                    <span class="stat-label">Reduction in NO bioavailability</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">#1</span>
                    <span class="stat-label">Killer of women globally</span>
                </div>
            </div>
        </div>

        <p>Nitric Oxide (NO) is a potent vasodilator. It keeps the arterial walls flexible, prevents platelet aggregation (clotting), and inhibits the migration of smooth muscle cells into the vessel lining (a key step in plaque formation). When E2 levels fluctuate and eventually drop, NO production plummets, leading to <strong>endothelial dysfunction</strong>‚Äîthe precursor to atherosclerosis.</p>

        <h2 id="lipids">2. Lipid Profile Shifts: The Hepatic Mechanism</h2>
        <p>During the transition from the late reproductive years to post-menopause, women experience a significant and often rapid shift in their lipid profiles that is independent of age or weight gain. A 2021 study in the <i>Journal of the American Heart Association</i> noted that <span class="highlight">LDL cholesterol increases by approximately 10-15%</span> during the one year surrounding the final menstrual period.</p>

        <p>Why does this happen? Estrogen regulates the expression of <strong>LDL receptors in the liver</strong>. When estrogen is abundant, the liver efficiently clears LDL particles from the blood. As estrogen declines, LDL receptor activity decreases, allowing LDL to circulate longer and become oxidized. Simultaneously, we often see a decrease in HDL (the "cholesterol scavenger") and an increase in <strong>Lipoprotein(a)</strong>, a highly genetic and inflammatory marker that becomes more prominent post-menopause.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Marker</th>
                        <th>Pre-Menopausal State</th>
                        <th>Post-Menopausal Shift</th>
                        <th>Mechanism</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>LDL Cholesterol</strong></td>
                        <td>Lower/Optimal</td>
                        <td>Increased (10-20%)</td>
                        <td>Reduced hepatic LDL receptor activity</td>
                    </tr>
                    <tr>
                        <td><strong>HDL Cholesterol</strong></td>
                        <td>Higher/Protective</td>
                        <td>Decreased or Dysfunctional</td>
                        <td>Loss of E2-mediated ApoA-I synthesis</td>
                    </tr>
                    <tr>
                        <td><strong>Triglycerides</strong></td>
                        <td>Stable</td>
                        <td>Increased</td>
                        <td>Shift in insulin sensitivity & VLDL clearance</td>
                    </tr>
                    <tr>
                        <td><strong>Vascular Stiffness</strong></td>
                        <td>Low (Compliant)</td>
                        <td>High (Rigid)</td>
                        <td>Loss of Nitric Oxide (NO) signaling</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="raas">3. RAAS & Blood Pressure Volatility</h2>
        <p>Many women report "sudden" hypertension during perimenopause, even those who were hypotensive (low blood pressure) their entire lives. This is frequently driven by the loss of <span class="highlight">Progesterone</span> and its interaction with the <strong>Renin-Angiotensin-Aldosterone System (RAAS)</strong>.</p>

        <p>Progesterone is a natural <strong>aldosterone antagonist</strong>. Aldosterone is a hormone that tells the kidneys to retain salt and water, which increases blood pressure. By competing for the same receptor, progesterone acts as a natural diuretic. When progesterone levels drop (often the first hormone to decline in perimenopause), aldosterone goes unchecked, leading to sodium retention, fluid volume expansion, and increased peripheral vascular resistance.</p>
        
        <p>Furthermore, the loss of estrogen increases the sensitivity of <strong>Angiotensin II receptors</strong> (AT1R), which causes vasoconstriction. This "double hit"‚Äîunchecked aldosterone and hypersensitive vasoconstriction‚Äîcreates the perfect storm for "menopausal hypertension."</p>

        <h2 id="window">4. The 'Window of Opportunity' Hypothesis</h2>
        <p>Perhaps the most critical concept for a Hormone Health Coach to understand is the <strong>Timing Hypothesis</strong>, or the "Window of Opportunity." This hypothesis explains the conflicting data from the Women's Health Initiative (WHI) study of 2002 versus more recent trials like KEEPS and ELITE.</p>

        <p>The hypothesis suggests that HRT has <span class="highlight">cardioprotective benefits when initiated close to the onset of menopause</span>, but may be harmful if started too late. </p>

        <div class="principle-card">
            <div class="principle-title">The Critical Timing Rule</div>
            <div class="principle-text">
                Current consensus (NAMS, 2022) indicates that for symptomatic women:
                <ul>
                    <li><strong>The Window:</strong> Initiation within 10 years of menopause or before age 60.</li>
                    <li><strong>Benefit:</strong> Reduction in all-cause mortality and significant reduction in coronary heart disease.</li>
                    <li><strong>The Risk:</strong> Initiation >20 years post-menopause or after age 70 may increase risk because estrogen can destabilize <i>pre-existing</i> advanced plaques.</li>
                </ul>
            </div>
        </div>

        <h2 id="markers">5. Advanced Markers: Moving Beyond the Standard Panel</h2>
        <p>Standard lipid panels often miss the "hidden" cardiovascular risk in menopausal women. To provide premium care, coaches should understand how to interpret <strong>subclinical inflammatory markers</strong>.</p>

        <p><strong>hs-CRP (High-Sensitivity C-Reactive Protein):</strong> A marker of systemic inflammation. In menopause, the increase in visceral fat (belly fat) produces inflammatory cytokines (IL-6, TNF-Œ±), which signal the liver to produce CRP. Levels above 2.0 mg/L in a menopausal woman suggest significant vascular inflammation.</p>

        <p><strong>Homocysteine:</strong> An amino acid that, when elevated, acts as a "corrosive" to the arterial lining. Estrogen helps keep homocysteine levels low by facilitating the methylation pathway. Post-menopause, homocysteine often rises, increasing the risk of stroke and heart attack independently of cholesterol.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë©‚Äç‚öïÔ∏è</div>
                <div>
                    <p class="box-label">Case Study: The "Sudden" Hypertensive</p>
                    <p class="subtitle">Managing the Perimenopausal Cardiac Shift</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah, Age 51</h4>
                        <p>Late Perimenopause | BMI 27 | Presenting with: Heart Palpitations & New-onset BP (145/92)</p>
                    </div>
                </div>
                <p><strong>Assessment:</strong> Sarah's BP was historically 110/70. Over 18 months, as her cycles became erratic, her BP rose and she developed "anxiety-like" heart palpitations. Her LDL rose from 115 to 160 mg/dL.</p>
                <p><strong>The Method Intervention:</strong>
                <ul>
                    <li><strong>Hormonal Support:</strong> Referral for bioidentical transdermal E2 and micronized progesterone (to antagonize aldosterone).</li>
                    <li><strong>Nutraceuticals:</strong> Magnesium Taurate (200mg BID) for palpitations and BP; 2g EPA/DHA for endothelial support.</li>
                    <li><strong>Lifestyle:</strong> Implementation of "Zone 2" cardiovascular training to stimulate eNOS production.</li>
                </ul>
                </p>
                <p><strong>Outcome:</strong> After 3 months, Sarah's BP stabilized at 122/78. Her LDL dropped to 138 mg/dL without statins, and palpitations resolved completely.</p>
            </div>
        </div>

        <h2 id="clinical">6. Practitioner Application: The Cardiovascular Checklist</h2>
        <p>As a coach, your role is to identify women entering this "Window of Opportunity" and facilitate the necessary testing and referrals. Use the following checklist when assessing clients aged 45-55:</p>

        <ul class="content-list">
            <li><strong>Monitor Blood Pressure Trends:</strong> Do not dismiss a 10-point rise as "stress." It is often a signal of declining progesterone and NO.</li>
            <li><strong>Assess Waist-to-Hip Ratio:</strong> Visceral fat is an endocrine organ that directly damages the heart via inflammatory cytokines.</li>
            <li><strong>Identify "Palpitation Patterns":</strong> Heart palpitations are a top-5 perimenopause symptom, often linked to autonomic nervous system shifts and mineral depletion (Magnesium/Potassium).</li>
            <li><strong>Educate on HRT Timing:</strong> Empower the client with the "Window of Opportunity" data so they can have informed conversations with their physician.</li>
        </ul>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <p class="question-text">1. Why does blood pressure often rise when progesterone levels fall during perimenopause?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Progesterone acts as a natural aldosterone antagonist. When it declines, aldosterone increases, leading to sodium and water retention and increased blood pressure.</div>
            </div>
            <div class="question-item">
                <p class="question-text">2. According to the "Window of Opportunity" hypothesis, what is the ideal timeframe to start HRT for cardiovascular protection?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Initiation should ideally occur within 10 years of the final menstrual period or before the age of 60.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>Estrogen is a Vasodilator:</strong> It maintains arterial flexibility by stimulating Nitric Oxide production.</li>
                <li><strong>Lipids Shift Rapidly:</strong> LDL increases and HDL decreases due to changes in hepatic receptor activity during the transition.</li>
                <li><strong>Timing is Everything:</strong> The cardiovascular benefits of HRT are highly dependent on starting during the "Window of Opportunity."</li>
                <li><strong>Progesterone Matters for BP:</strong> Its role in the RAAS system makes it a critical component of blood pressure management.</li>
                <li><strong>Look Beyond Cholesterol:</strong> Use hs-CRP and Homocysteine to get a clearer picture of vascular inflammation.</li>
            </ul>
        </div>

        <div class="references-box">
            <p class="box-label">References & Further Reading</p>
            <p>1. El Khoudary, S. R., et al. (2020). "Menopause Transition and Cardiovascular Disease Risk: Implications for Surveillance and Prevention." <i>Circulation</i>.</p>
            <p>2. Manson, J. E., et al. (2013). "The Menopause Study: Hormone Therapy and Cardiovascular Health." <i>Journal of the American Medical Association (JAMA)</i>.</p>
            <p>3. Hodis, H. N., et al. (2016). "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE Trial)." <i>New England Journal of Medicine</i>.</p>
            <p>4. Miller, V. M., et al. (2014). "The Kronos Early Estrogen Prevention Study (KEEPS): Mid-study results." <i>Menopause</i>.</p>
            <p>5. NAMS. (2022). "The 2022 Hormone Therapy Position Statement of The North American Menopause Society." <i>Menopause Journal</i>.</p>
            <p>6. Rossouw, J. E., et al. (2002). "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women (WHI Trial)." <i>JAMA</i>.</p>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Women's Hormone Health Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>